newsfilter
← Latest News
Business Wire·

CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection

Draft Policy Recognizes the Importance of Surveillance Testing for Early Detection of Allograft Rejection in Kidney, Heart, and Lung CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision